The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin E-Cdk2
Open accessAbstract
Estrogens induce cell proliferation in target tissues by stimulating progression through G1 phase of the cell cycle, but the underlying molecular targets remain undefined. To determine the role of the cyclin/cyclin-dependent kinase (CDK)/retinoblastoma protein (pRB) pathway in this response we treated MCF-7 breast cancer cells with the pure estrogen antagonist ICI 182780 to inhibit estrogen-induced gene expression and induce G1 phase arrest. Subsequent treatment with 17beta-estradiol resulted in the synchronous entry of cells into S phase commencing at 12 h. The proportion of cells in S phase reached a maximum of 60% at 21-24 h. Cells subsequently completed mitosis and entered a second semisynchronous round of replication. Entry into S phase was preceded by increased activity of both Cdk4 and cyclin E-Cdk2 and hyperphosphorylation of pRB, all within the first 3-6 h of estradiol treatment. The increase in Cdk4 activity was accompanied by increases in cyclin D1 mRNA and protein, indicating that an initiating event in the activation of Cdk4 was increased cyclin D1 gene expression. In contrast, the levels of Cdk2 and the CDK inhibitors p21 (WAF1/CIP1/SDI1) and p27 (KIP1) in total cell lysates and in cyclin E immunoprecipitates were unaltered at these early time points. However, an inhibitory activity was present in antiestrogen-pretreated cell lysates toward recombinant cyclin E-Cdk2 and was relieved by estradiol treatment. This activity was attributable predominantly to p21. These apparently conflicting data were resolved by performing gel filtration chromatography, which revealed that only a minority of cyclin E-Cdk2 complexes were active following estradiol treatment. Active complexes eluted at a higher molecular weight than inactive complexes, were relatively deficient in both p21 and p27, and contained Cdk2 with increased threonine 160 phosphorylation, consistent with a mechanism of activation of cyclin E-Cdk2 involving both reduced CDK inhibitor association and CDK-activating kinase-mediated phosphorylation of Cdk2. These results provide an explanation for the early activation of both cyclin D1-Cdk4 and cyclin E-Cdk2 complexes that accompany G1-S phase progression in response to estradiol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p21 is a potent inhibitor of binding to cyclin-dependent kinases (CDKs), which inhibits cell cycle proteins and further inhibits phosphorylation of Rb by the cyclin D1-CDK4, cyclin D2-CDK4 and cyclin E-CDK2 complexes.56–58”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
Antibodies: A laboratory manual
J.L. (1989) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(89)90307-1 · Cited by 5,089
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Morgan, D. O. (1995) · Nature · doi:10.1038/374131a0 · Cited by 3,284
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,043
Sherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
Cited by
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Björnström, L., & Sjöberg, M. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0486 · Cited by 1,362
Molecular Cues to Implantation
Dey, S. K., Lim, H., Das, S. K., Reese, J., Paria, B. C., Daikoku, T., & Wang, H. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0020 · Cited by 1,105
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 676
Migliaccio, A., Piccolo, D., Castoria, G., Di Domenico, M., Bilancio, A., Lombardi, M., Gong, W., Beato, M., & Auricchio, F. (1998) · The EMBO Journal · doi:10.1093/emboj/17.7.2008 · Cited by 626
Estrogen Signaling Multiple Pathways to Impact Gene Transcription
Marino, M., Galluzzo, P., & Ascenzi, P. (2006) · Current Genomics · doi:10.2174/138920206779315737 · Cited by 619
Ström, A., Hartman, J., Foster, J. S., Kietz, S., Wimalasena, J., & Gustafsson, J.-Å. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308319100 · Cited by 534
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Structure–function relationship of estrogen receptor α and β: Impact on human health
Ascenzi, P., Bocedi, A., & Marino, M. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.07.001 · Cited by 499
Role of Estrogen Receptor Beta in Estrogen Action
Pettersson, K., & Gustafsson, J.-Å. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.165 · Cited by 491
Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression
Liu, M.-M., Albanese, C., Anderson, C. M., Hilty, K., Webb, P., Uht, R. M., Price, R. H., Pestell, R. G., & Kushner, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201829200 · Cited by 422
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
Pestell, R. G., Albanese, C., Reutens, A. T., Segall, J. E., Lee, R. J., & Arnold, A. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0373 · Cited by 375
Estrogen induction of the cyclin D1 promoter: Involvement of a cAMP response-like element
Sabbah, M., Courilleau, D., Mester, J., & Redeuilh, G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11217 · Cited by 365
A CTCF-independent role for cohesin in tissue-specific transcription
Schmidt, D., Schwalie, P. C., Ross-Innes, C. S., Hurtado, A., Brown, G. D., Carroll, J. S., Flicek, P., & Odom, D. T. (2010) · Genome Research · doi:10.1101/gr.100479.109 · Cited by 358
Lee, A. V. (1999) · Molecular Endocrinology · doi:10.1210/me.13.5.787 · Cited by 340
Boulay, A., Rudloff, J., Ye, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S., & Lane, H. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2402 · Cited by 335
Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells
Doisneau-Sixou, S. F., Sergio, C. M., Carroll, J. S., Hui, R., Musgrove, E. A., & Sutherland, R. L. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100179 · Cited by 333
Self-citationChen, H. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh161 · Cited by 290
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285
Cover, C. M., Hsieh, S. J., Tran, S. H., Hallden, G., Kim, G. S., Bjeldanes, L. F., & Firestone, G. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.7.3838 · Cited by 282
c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry
Prall, O. W. J., Rogan, E. M., Musgrove, E. A., Watts, C. K. W., & Sutherland, R. L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.8.4499 · Cited by 267
Self-citationLouie, M. C., Zou, J. X., Rabinovich, A., & Chen, H.-W. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5157-5171.2004 · Cited by 259
Sutherland, R. L., & Musgrove, E. A. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000023591.45568.77 · Cited by 258
Self-citationBRCA1 transcriptionally regulates genes involved in breast tumorigenesis
Welcsh, P. L., Lee, M. K., Gonzalez-Hernandez, R. M., Black, D. J., Mahadevappa, M., Swisher, E. M., Warrington, J. A., & King, M.-C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062181799 · Cited by 256
Role of sex steroid receptors in pathobiology of hepatocellular carcinoma
Kalra, M., Mayes, J., Assefa, S., Kaul, A. K., & Kaul, R. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.5945 · Cited by 141
Differential regulation of cyclins D1 and D3 in hepatocyte proliferation
Rickheim, D. G., Nelsen, C. J., Fassett, J. T., Timchenko, N. A., Hansen, L. K., & Albrecht, J. H. (2002) · Hepatology · doi:10.1053/jhep.2002.33996 · Cited by 112
Pramparo, T., Lombardo, M. V., Campbell, K., Barnes, C. C., Marinero, S., Solso, S., Young, J., Mayo, M., Dale, A., Ahrens‐Barbeau, C., et al. (2015) · Molecular Systems Biology · doi:10.15252/msb.20156108 · Cited by 88
“Similarly, the ESR1 pathway acts like a ligand-dependent transcription factor and promotes G1/S transition through several pathways (Prall et al, 1997; Foster et al, 2001).”
Butt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-78818-0_12 · Cited by 59
Self-citationCombined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo
Chen, Y., Alvarez, E. A., Azzam, D., Wander, S. A., Guggisberg, N., Jordà, M., Ju, Z., Hennessy, B. T., & Slingerland, J. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1024-7 · Cited by 54
CAPER, a novel regulator of human breast cancer progression
Mercier, I., Gonzales, D. M., Quann, K., Pestell, T. G., Molchansky, A., Sotgia, F., Hulit, J., Gandara, R., Wang, C., Pestell, R. G., et al. (2014) · Cell Cycle · doi:10.4161/cc.28156 · Cited by 45
“1260 Cell Cycle Volume 13 Issue 8 The proliferative effects of estrogens on mammary epithelial cells are well known to be mediated, at least in part, through the regulation of genes involved in cell cycle progression.(27) Interestingly, both our western blot and immunohistochemical analyses show reduced expression of…”
BackgroundAlmeida, M., Han, L., O’Brien, C. A., Kousteni, S., & Manolagas, S. C. (2006) · Endocrinology · doi:10.1210/en.2005-1314 · Cited by 40
CDK4 expression and activity are required for cytokine responsiveness in T cells
Modiano, J. F., Mayor, J., Ball, C., Fuentes, M. K., & Linthicum, D. S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.6693 · Cited by 29
Sirianni, R., Capparelli, C., Chimento, A., Panza, S., Catalano, S., Lanzino, M., Pezzi, V., & Andò, S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.002 · Cited by 25
“One mechanism through which estrogens can induce cell proliferation is through up-regulation of the expression of cell cycle G1 phase regulatory cyclins in target cells (Ma et al., 2009; Prall et al., 1997).”
Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors
Wiedemeyer, W. R. (2018) · Resistance to Targeted Anti-Cancer Therapeutics · doi:10.1007/978-3-319-67932-7_8 · Cited by 7
Metadata
- Authors
- Prall, O. J., Sarcevic, B., Musgrove, E. A., Watts, C. W., & Sutherland, R. L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1997-04
- Volume
- 272
- Issue
- 16
- Pages
- 10882-10894
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2093465294
- Cited by
- 444
- References
- 86
- FWCI
- 10.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.